In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells

Published:2021-04 Issue:2 Volume:25 Page:126-134
ISSN:1278-3218
Container-title:Cancer/Radiothérapie
language:en
Short-container-title:Cancer/Radiothérapie

Author:

Mignot F.,Kirova Y.,Verrelle P.,Teulade-Fichou M.-P.,Megnin-Chanet F.

Funder

Institut Curie

Institut National de la Santé et de la Recherche Médicale

Centre National de la Recherche Scientifique

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference35 articles.

1. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Senkus;Ann Oncol,2015

2. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology;Gradishar;J Nat Comp Cancer Net,2018

3. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate;Lewis Phillips;Can Res,2008

4. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

5. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial;Krop;Lancet Oncol,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates;Critical Reviews in Oncology/Hematology;2024-03

2. Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment;Acta Pharmaceutica Sinica B;2023-11

3. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis;Radiotherapy and Oncology;2023-09

4. Traitements systémiques ciblés et radiothérapie locorégionale pour les cancers du sein : peut-on espérer un bénéfice de la potentialisation du traitement local ?;Cancer/Radiothérapie;2023-09

5. Radiothérapie et thérapie ciblée pour la prise en charge du cancer du sein : mise au point;Cancer/Radiothérapie;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3